Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Illumina Laboratory Services, |
RCV000504965 | SCV000914732 | likely pathogenic | Retinitis pigmentosa | 2018-10-18 | criteria provided, single submitter | clinical testing | The CNGB1 c.413-1G>A variant has been reported in three studies in at least four probands with retinitis pigmentosa, all in a homozygous state (Azam et al. 2011; Saqib et al. 2015; van Huet et al. 2015). Two of these probands were siblings and their unaffected parents were shown to carry the variant in a heterozygous state. Control data are not available for this variant which is reported at a frequency of 0.00024 in the South Asian population from the Exome Aggregation Consortium. When this variant was incorporated into a vector which was transfected into HeLa cells and retrotranscribed, the cDNA demonstrated a frameshift and introduction of a premature stop codon (Saqib et al. 2015). Based on the evidence and due to the potential impact of splice acceptor variants, the c.413-1G>A variant is classified as likely pathogenic for autosomal recessive retinitis pigmentosa. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. |
Labcorp Genetics |
RCV001056559 | SCV001221009 | pathogenic | not provided | 2025-01-13 | criteria provided, single submitter | clinical testing | This sequence change affects an acceptor splice site in intron 6 of the CNGB1 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or altered protein product. This variant is present in population databases (rs189234741, gnomAD 0.03%). Disruption of this splice site has been observed in individuals with retinitis pigmentosa (PMID: 25943428). It has also been observed to segregate with disease in related individuals. This variant is also known as IVS6-1G>A. ClinVar contains an entry for this variant (Variation ID: 437976). Studies have shown that disruption of this splice site results in activation of a cryptic splice acceptor, and produces a non-functional protein and/or introduces a premature termination codon (PMID: 25943428). For these reasons, this variant has been classified as Pathogenic. |
Blueprint Genetics | RCV001074746 | SCV001240341 | pathogenic | Retinal dystrophy | 2019-05-16 | criteria provided, single submitter | clinical testing | |
Ocular Genomics Institute, |
RCV000678544 | SCV001573652 | pathogenic | Retinitis pigmentosa 45 | 2021-04-08 | criteria provided, single submitter | research | The CNGB1 c.413-1G>A variant was identified in an individual with retinitis pigmentosa with a presumed recessive inheritance pattern. Through a review of available evidence we were able to apply the following criteria: PVS1, PP1-M, PM3, PM2. Based on this evidence we have classified this variant as Pathogenic. |
Fulgent Genetics, |
RCV000678544 | SCV002815791 | pathogenic | Retinitis pigmentosa 45 | 2024-05-10 | criteria provided, single submitter | clinical testing | |
Institute of Human Genetics, |
RCV001074746 | SCV005073079 | pathogenic | Retinal dystrophy | 2023-01-01 | criteria provided, single submitter | clinical testing | |
NIHR Bioresource Rare Diseases, |
RCV000504965 | SCV000598716 | pathogenic | Retinitis pigmentosa | 2015-01-01 | no assertion criteria provided | research | |
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000678544 | SCV000804622 | pathogenic | Retinitis pigmentosa 45 | 2016-09-01 | no assertion criteria provided | clinical testing | |
Sharon lab, |
RCV000504965 | SCV001161025 | pathogenic | Retinitis pigmentosa | 2019-06-23 | no assertion criteria provided | research |